Publications by authors named "B El Fatemi"
Objective: The main aim of this study was to explore and understand the emerging developments, changes, and patterns shaping the future of the pharmaceutical industry. The pharmaceutical industry is evolving rapidly due to scientific breakthroughs, societal changes, and technological advancements. Companies can adapt, and innovate to stay competitive and advance healthcare objectives by understanding the changes and patterns shaping the future.
View Article and Find Full Text PDFArticle Synopsis
- The article presents the first national guidelines for managing acute coronary syndrome (ACS) in Iran, detailing diagnosis, treatment, and secondary prevention strategies.
- A group of specialists examined clinical concerns and formulated 13 key questions, leading to recommendations based on systematic evidence review.
- The guidelines include initial response protocols for chest pain, risk categorization for patients, treatment options in hospitals, and strategies for secondary prevention post-ACS.
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis.
Expert Rev Pharmacoecon Outcomes Res
January 2025
Background: As rheumatoid arthritis (RA) is a chronic and progressive disease that requires lifelong therapeutic intervention, it represents a considerable economic burden on those affected. This study investigated whether tofacitinib is a cost-effective therapeutic alternative to other DMARDs for treating moderate-to-severe RA.
Research Design And Methods: All economic evaluation studies of tofacitinib compared to other DMARDs were identified.
Article Synopsis
- This guideline is Iran's first systematic approach for diagnosing and managing hyperlipidemia in adults, addressing key clinical questions with evidence-based recommendations.
- It sets specific thresholds for LDL-C (over 190 mg/dL) and triglycerides (over 500 mg/dL) to initiate drug treatment while emphasizing lifestyle changes as the primary intervention.
- Statins are recommended as the first-line medication, with additional options proposed for high levels, and targets for LDL-C (<130 mg/dL) and triglycerides (<200 mg/dL) are specified for adults without comorbidities.
Background And Purpose: Though controversial, many clinical trials have been conducted to evaluate the efficacy of intravenous immunoglobulins (IVIG) in COVID-19 cases. Therefore, a systematic review and meta-analysis have been performed to evaluate the efficacy of IVIG in the treatment of COVID-19 patients.
Experimental Approach: A systematic search was performed in electronic databases and preprint servers up to November 20, 2021.